Maintaining functional and behavioral abilities in Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 15, Issue SUPPL. 1, 2001, Pages

  Winblad, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer disease; Behavioral benefit; Caregiver; Functional benefit; Galantamine; Quality of time

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BEHAVIOR; CAREGIVER; CONFERENCE PAPER; DISTRESS SYNDROME; DRUG ACTIVITY; DRUG MECHANISM; FUNCTIONAL ASSESSMENT; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034868725     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200108001-00006     Document Type: Conference Paper

References (54)

1. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function
2. The cholinergic hypothesis of geriatric memory dysfunction
3. Commentary: Another piece of the Alzheimer's jigsaw
4. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished
5. Galantamine: Therapeutic effects beyond cognition
6. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
7. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research
8. Canadian study of health. Aging patterns of caring for people with dementia in Canada
9. Psychometric evaluation of the Pittsburgh sleep quality index
10. Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease
11. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
12. Alzheimer's disease: A disorder of cortical cholinergic innervation
13. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients
14. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
15. Cholinergic markers in elderly patients with early signs of Alzheimer disease
16. Measurement of quality-of-life changes in patients with Alzheimer's disease
17. An inventory to assess the activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study
18. Do we have a treatment for Alzheimer's disease? Yes
19. Functional disability in Alzheimer's disease
20. Functional autonomy
21. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia
22. Special workshop in dementia with Lewy bodies
23. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
24. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity
25. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
26. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease
27. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
28. Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial
29. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
30. The economic impact of Alzheimer's disease
31. Acute nicotinic blockade produces cognitive impairment in normal humans
32. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics
33. Neuroreceptor changes in Alzheimer disease
34. Neuronal nicotinic receptors in the human brain
35. Do we have drugs for dementia? No
36. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease
37. Galantamine in Alzheimer's disease - A 6-month randomized, placebo-controlled trial with a 6-month extension
38. Galantamine's clinical benefits are not offset by sleep disturbance: A 3-month placebo-controlled study in patients with Alzheimer's disease
39. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
40. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
41. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study
42. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
43. A new rating scale for Alzheimer's disease
44. Assessing outcomes in Alzheimer disease
45. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands
46. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease
47. Galantamine postpones the emergence of behavioral symptoms in Alzheimer's disease: A 5-month, placebo-controlled study
48. Behavioral disturbance, cognitive dysfunction, and functional skill. Prevalence and relationship in Alzheimer's disease
49. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine
50. 12-Month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: Two randomized, placebo-controlled studies
51. Galantamine alleviates caregiver burden in Alzheimer's disease: 6-month placebo-controlled study
52. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group
53. Galantamine improves activities of daily living in patients with Alzheimer's disease: A 3-month placebo-controlled study
54. Presynaptic nicotinic ACh receptors